Hopman W P, van Liessum P A, Pieters G F, Smals A G, Tangerman A, Jansen J B, Rosenbusch G, Lamers C B, Kloppenborg P W
Division of Gastroenterology, University Hospital Nijmegen, The Netherlands.
Digestion. 1990;45 Suppl 1:72-6. doi: 10.1159/000200266.
Since octreotide (SMS 201-995, Sandostatin; Sandoz Pharmaceuticals) is a potent inhibitor of pancreatic exocrine secretion and gallbladder contraction, long-term treatment with this drug may theoretically result in impaired pancreatic function and gallstones. However, we observed excellent pancreatic exocrine function--as assessed by the PABA/PAS test--in acromegalics who received octreotide treatment for more than 6 months. Plasma cholecystokinin showed a significant, although blunted, postprandial response, which exceeded the threshold for gallbladder contraction in healthy controls. Remarkably, postprandial gallbladder contraction was completely abolished for at least 2 h during octreotide treatment. In contrast to other studies, none of 16 acromegalic patients on long-term octreotide treatment developed gallstones. Although the incidence of gallstones in patients on long-term octreotide treatment may be increased, the risk seems to be variable.
由于奥曲肽（SMS 201-995，善宁；山德士制药公司）是胰腺外分泌和胆囊收缩的强效抑制剂，理论上长期使用该药可能会导致胰腺功能受损和胆结石。然而，我们观察到，在接受奥曲肽治疗超过6个月的肢端肥大症患者中，通过对氨基苯甲酸/对氨基水杨酸试验评估，其胰腺外分泌功能良好。血浆胆囊收缩素在餐后有显著反应，尽管有所减弱，但超过了健康对照组胆囊收缩的阈值。值得注意的是，在奥曲肽治疗期间，餐后胆囊收缩至少在2小时内完全消失。与其他研究不同，16例接受长期奥曲肽治疗的肢端肥大症患者均未出现胆结石。虽然长期接受奥曲肽治疗的患者胆结石发生率可能会增加，但风险似乎因人而异。
